Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| enterocyte | 6 studies | 36% ± 10% | |
| goblet cell | 5 studies | 26% ± 7% | |
| epithelial cell | 4 studies | 31% ± 8% | |
| enteroendocrine cell | 3 studies | 34% ± 0% | |
| brush cell | 3 studies | 18% ± 3% | |
| hepatocyte | 3 studies | 41% ± 24% |
Insufficient scRNA-seq data for expression of TM4SF5 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 3866.26 | 226 / 226 | 96% | 559.93 | 389 / 406 |
| stomach | 75% | 196.32 | 270 / 359 | 83% | 62.91 | 238 / 286 |
| kidney | 91% | 303.82 | 81 / 89 | 48% | 23.19 | 436 / 901 |
| intestine | 49% | 365.37 | 470 / 966 | 84% | 57.00 | 444 / 527 |
| pancreas | 10% | 5.63 | 33 / 328 | 71% | 67.41 | 126 / 178 |
| esophagus | 1% | 0.84 | 8 / 1445 | 39% | 38.38 | 72 / 183 |
| bladder | 0% | 0 | 0 / 21 | 20% | 12.94 | 102 / 504 |
| lung | 0% | 0.07 | 1 / 578 | 14% | 12.85 | 167 / 1155 |
| uterus | 0% | 0 | 0 / 170 | 5% | 2.66 | 22 / 459 |
| peripheral blood | 1% | 3.65 | 13 / 929 | 0% | 0 | 0 / 0 |
| breast | 1% | 0.80 | 4 / 459 | 0% | 0.28 | 1 / 1118 |
| adrenal gland | 0% | 0 | 0 / 258 | 1% | 0.28 | 2 / 230 |
| ovary | 1% | 0.18 | 1 / 180 | 0% | 0 | 0 / 430 |
| spleen | 0% | 3.86 | 1 / 241 | 0% | 0 | 0 / 0 |
| adipose | 0% | 0.68 | 4 / 1204 | 0% | 0 | 0 / 0 |
| thymus | 0% | 0.29 | 2 / 653 | 0% | 0 | 0 / 605 |
| heart | 0% | 0.04 | 1 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 0% | 0.05 | 1 / 1335 | 0% | 0 | 0 / 0 |
| skin | 0% | 0.04 | 1 / 1809 | 0% | 0 | 0 / 472 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| brain | 0% | 0 | 0 / 2642 | 0% | 0 | 0 / 705 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| prostate | 0% | 0 | 0 / 245 | 0% | 0 | 0 / 502 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_2000045 | Biological process | regulation of G1/S transition of mitotic cell cycle |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0034618 | Molecular function | arginine binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | TM4SF5 |
| Protein name | Transmembrane 4 L6 family member 5 (Tetraspan transmembrane protein L6H) TM4SF5 protein |
| Synonyms | |
| Description | FUNCTION: Acts as a lysosomal membrane arginine sensor . Forms a complex with MTOR and SLC38A9 on lysosomal membranes in an arginine-regulated manner, leading to arginine efflux which enables the activation of mTORC1 which subsequently leads to RPS6KB1 and EIF4EBP1 phosphorylations . Facilitates cell cycle G1/S phase progression and the translocation of the CDK4-CCND1 complex into the nucleus . CDKN1B and RHOA/ROCK signaling activity are involved in TM4SF5-mediated acceleration of G1/S phase progression . . |
| Accessions | ENST00000270560.4 Q6FHF6 O14894 |